@article{c4bd039f63cd41bead8dd3a2ee1b9165,
title = "Optimal benefits for hematopoietic stem cell transplantation: A consensus opinion",
abstract = "Variability in transplantation benefits may directly affect outcomes of individuals undergoing autologous or allogeneic hematopoietic stem cell transplantation procedures. The Financial Working Group of the National Marrow Donor Program-sponsored System Capacity Initiative addressed the issue of variable benefits and reviewed multiple transplantation benefit packages from both public and private payer organizations. On completion of the review, a consensus was obtained on defining a recipient benefit package that avoids major coverage gaps that could negatively influence patient outcomes. The recommendation was to encourage adoption of these benefits at a national level by payers, benefit brokers/consultants, and sales teams.",
keywords = "Consensus, Hematopoietic stem cell transplantation",
author = "Maziarz, {Richard T.} and Stephanie Farnia and Patricia Martin and Komanduri, {Krishna V.}",
note = "Funding Information: Coverage of clinical trial participation should be provided for trials appropriate to the patient's disease, stage, and clinical condition. Routine costs associated with clinical trials that are federally approved or sponsored (eg, HCT trials supported by the National Heart Lung Blood Institute (NHLBI) and National Cancer Institutes (NCI), including multicenter or single center studies performed at NCI-designated cancer centers) are required of most health insurance policies as of January 1, 2014, under the provisions of the ACA. However, coverage for well-designed clinical trials that have not secured federal funding should also be considered when recommended by a patient's care team, particularly for emerging transplantation indications. Well-designed, statistically sound, single institution, scientifically innovative trials, such as the recently published studies of chimeric antigen receptor-T cells in relapsed acute lymphoid leukemia from the University of Pennsylvania Abramson Cancer Center have played an important role in furthering the HCT field [12] . Limiting patient access only to multicenter, well-designed, nationally supported clinical trials has the risk of slowing improvement in standards of care that otherwise would continue to evolve at a high rate, given the rapid pace of scientific and clinical developments relevant to HCT. Paying for identical care outside of a clinical trial has identical cost without the collective societal benefit gained via clinical trials. HCT is an area of medicine with a high proportion of patients treated on clinical trials because of the complexity of the treatment, the variety of diseases treated, and the rapid evolution of best practices, including those efforts spearheaded by research consortiums that include the NHLBI- and NCI-sponsored Blood and Marrow Transplant Clinical Trials Network [13,14] . Publisher Copyright: {\textcopyright} 2014 American Society for Blood and Marrow Transplantation.",
year = "2014",
month = nov,
day = "1",
doi = "10.1016/j.bbmt.2014.07.007",
language = "English (US)",
volume = "20",
pages = "1671--1676",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "11",
}